Val Romberg is responsible for CSL Behring’s state-of-the-art global manufacturing and plasma collection operations with sites in Germany, Australia, Switzerland, China and the U.S., where the company’s biotherapies are produced. He is also accountable for Planning.
Val has more than 30 years of experience in the pharmaceutical industry. In 1998 he joined Centeon, a predecessor company of CSL Behring, where he has held a broad range of positions. These include project management in King of Prussia, US, where he was involved in the development of recombinant and plasma-derived products.
Since 2003, he has served in several management roles, including Technical Operations in Kankakee, USA for Aventis Behring, also a predecessor company of CSL Behring. In July 2006, he became Senior Director, Research & Development (R&D), in Bern, Switzerland, focusing on the development of immunoglobulins. Val became Senior Vice President, Global R&D, CSL Behring in 2007.
When R&D was integrated into a single global operation in 2011, Val assumed the role of Senior Vice President, Plasma Product R&D. During his R&D tenure, CSL Behring had more than 25 product or indication approvals in the US, Europe and Japan.
Val received a bachelor’s degree in chemistry from the University of Michigan.